Skip to content


    DEA Class; Rx

    Common Brand Names; Troxyca ER

    • Opioid Analgesics; 
    • Opioid Antagonists

    Opioid agonist/opioid antagonist combination product

    Oxycodone: Opioid agonist; relatively selective for the mu receptor, but it can bind to other opioid receptors at higher doses; inhibits ascending pain pathways, thus altering response to pain; produces analgesia, respiratory depression, and sedation

    Naltrexone: Opioid competitive receptor antagonist; shows highest affinity for mu receptors

    Indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

    To be prescribed only by healthcare providers knowledgeable in use of potent opioids for management of chronic pain

    Patients with significant respiratory depression

    Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment

    Known or suspected GI obstruction, including paralytic ileus

    Hypersensitivity (eg, anaphylaxis) to oxycodone or naltrexone or any other components of the formulation

    • Nausea (7-8%)
    • Vomiting (2-5%)
    • Headache (3-4%)
    • Constipation (3%)
    • Abdominal pain (3%)
    • Back pain (3%)
    • Anxiety (1-3%)
    • Pruritus (2%)
    • Insomnia (1-2%)
    • Gastrointestinal disorders: Abdominal pain, constipation, diarrhea, nausea, and vomiting
    • General disorders and administration site conditions: Drug withdrawal syndrome, fatigue, pain, malaise, and drug ineffective
    • Injury, poisoning, and procedural complications: Inadequate analgesia
    • Neoplasms benign, malignant, and unspecified (including cysts and polyps): Malignant neoplasm progression
    • Nervous system disorders: Dizziness, headache, tremor, and somnolence
    • Psychiatric disorders: Restlessness, confusional state, and anxiety
    • Respiratory, thoracic, and mediastinal disorders: Dyspnea
    • Skin and subcutaneous tissue disorders: Hyperhidrosis and pruritus

    Contains oxycodone, a Schedule II controlled drug; as an opioid, oxycodone/naltrexone exposes users to the risks of addiction, abuse, and misuse; as extended-release products (eg, Troxyca ER) deliver the opioid over an extended period, there is a greater risk for overdose and death owing to the larger amount of oxycodone present (see Black Box Warnings)

    Prolonged use during pregnancy can result in neonatal withdrawal syndrome that may be fatal if not recognized and managed by neonatal experts (see Black Box Warnings)

    Adrenal insufficiency reported with opioid use (greater incidence if used >1 month); if adrenal insufficiency diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid

    Severe hypotension reported, including orthostatic hypotension and syncope in ambulatory patients; risk increases in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazine, general anesthetics); monitor for severe hypotension during dosage initiation and titration; avoid use with circulatory shock

    Oxycodone/naltrexone may further reduce respiratory drive and exacerbate CO2 retention in patients with increased ICP or brain tumors; may also obscure the clinical course in a patient with a head injury; avoid use with impaired consciousness or coma


    Prolonged use during pregnancy may cause neonatal opioid withdrawal syndrome (see Black Box Warnings)


    Oxycodone is present in breast milk; because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, breastfeeding is not recommended during treatment with oxycodone/naltrexone


    Opioid-naïve or nonopioid-tolerant patients

    • Starting dose: 10 mg/1.2 mg PO q12hr
    • Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression

    Dose titration

    • Individually titrate dose to provide adequate analgesia and minimal adverse effects
    • Steady-state plasma concentrations are achieved within 48 hr
    • May be up-titrated from current dose by increasing daily dose in increments of 20 mg/2.4 mg per day q2-3 days as needed based on efficacy, safety, and tolerability
    • If breakthrough pain experienced, assess need for a dosage increase or a rescue dose of an immediate-release analgesic

    Opioid-tolerant patients

    • See Administration section for conversion from other PO oxycodone formulations or other opioids to Troxyca ER
    • Patients who are opioid tolerant are those receiving the following for ≥1 week
      • ≥60 mg/day PO morphine
      • ≥25 mcg/hr transdermal fentanyl
      • ≥30 mg/day PO oxycodone
      • ≥8 mg/day PO hydromorphone
      • ≥25 mg/day PO oxymorphone, OR
      • Equianalgesic dose of another opioid


    <18 years: Safety and efficacy not established


    Drug is substantially excreted in the urine; cautious, conservative use is advised with use in elderly individuals

    Oxycodone Hydrochloride/naltrexone

    extended-release capsule

    • 10mg/1.2mg
    • 20mg/2.4mg
    • 30mg/3.6mg
    • 40mg/4.8mg
    • 60mg/7.2mg
    • 80mg/9.6mg